BuzzSparks.org

Novo A/S


Novo A/S is the holding company of the Novo Group, wholly-owned by the Novo Nordisk Foundation. Novo A/S is the majority shareholder in the publicly listed companies Novo Nordisk A/S and Novozymes A/S. Novo A/S’ objective is to manage the...

Founded in 1999
Homepage:

HQ

Hellerup Tuborg Havnevej 19

Hellerup
Hellerup
DNK
Updated on Apr 12, 2013
Novo A/S at CrunchBase
Thorkil K. Christensen CFO
Tiba Aynechi Venture Group
Jack Nielson Partner
Scott A. Beardsley Partner
Søren Carlsen Managing Partner
Martin Edwards Senior Partner
Heather Ludvigsen Venture Auditor
Lone Penby Venture Coordinator
Hanne Falk Estrup Coordinator
Nanna Lüneborg Principal
Dorte Barlebo Madsen HR Director
Søren Møller Managing Investment Director at Novo Seeds
Jørgen Rønnow General Counsel
Michael Shalmi Senior Partner
Heath Lukatch Partner
Thomas Dyrberg Partner
Peter Bisgaard Partner
Kim Dueholm Partner
Cory Freedland Principal
Peter Moldt Partner
Nicole Zilveti Office Manager
Morten Beck Jørgensen Investment Director
Max Løwe Controller
Berit Mikkelsen Novo Seeds
Henrijette Ricther Investment Director
Susanne Schou Adm.Coordinator, Novo Growth Equity
Bobby Soni Principal with Novo Seeds
Past
Ulrik Spork Senior Partner

September, 2013

Novo A/S invested $23.5M in Acacia Pharma as a Series B round

August, 2013

Novo A/S invested $34.6M in ObsEva as a Series A round

June, 2013

Novo A/S invested $41M in Akebia Therapeutics as a Series C round

May, 2013

Novo A/S invested $50M in Ophthotech as a Series C round

Novo A/S invested $125M in Ophthotech as private_equity round

Novo Acquires Anti-Infective Developer Xellia for $700M    genengnews.com

Novo A/S invested $55.4M in Symphogen as private_equity round

March, 2013

Novo A/S invested $60M in PTC Therapeutics as unattributed round

September, 2012

Novo A/S invested $7.6M in Karus Therapeutics as a Series B round

July, 2012

Novo A/S invested $30M in PTC Therapeutics as unattributed round

June, 2012

Novo A/S invested $12M in Santaris Pharma as unattributed round

April, 2012

Novo A/S invested $20M in Inogen as unattributed round

Novo A/S invested $25M in AlloCure as a Series B round

March, 2012

Novo A/S invested $28M in Tarsa Therapeutics as a Series B round

February, 2012

Novo A/S invested $12.5M in Altheos as a Series A round

September, 2011

Novo A/S invested $20M in Orphazyme as a Series A round

August, 2011

Novo A/S invested $12.7M in KalVista Pharmaceuticals as a Series A round

July, 2011

Novo A/S invested $6.5M in Vantia Therapeutics as a Series B round

February, 2011

Novo A/S invested $15.7M in HTG Molecular Diagnostics as a Series D round

Novo A/S invested $15.7M in High Throughput Genomics as a Series D round

Novo A/S invested $135.4M in Symphogen as a Series F round

Novo A/S invested unknown amount in Orphazyme as seed round

January, 2011

Novo A/S invested $135M in Symphogen as unattributed round

October, 2010

Novo A/S invested $20M in ProteinSimple as a Series F round

Novo A/S invested $30M in Synosia Therapeutics as a Series C round

September, 2010

Novo A/S invested $31M in Tobira Therapeutics as a Series B round

July, 2010

Novo A/S invested $78M in Reata Pharmaceuticals as unattributed round

May, 2010

Novo A/S invested $16.9M in Logical Therapeutics as a Series C round

Novo A/S invested unknown amount in Nanoference as unattributed round

April, 2010

Novo A/S invested $99M in Archimedes Pharma as a Series C round

Novo A/S invested $20M in Altheos as a Series A round

December, 2009

Novo A/S invested $50M in PTC Therapeutics as a Series E round

Novo A/S invested $30M in Ophthotech as a Series B round

Novo A/S invested $4M in ProteinSimple as unattributed round

October, 2009

Novo A/S invested $50M in Lux Biosciences as a Series B round

April, 2009

Novo A/S invested $10M in ProteinSimple as a Series C round

November, 2007

Novo A/S invested $4.1M in f-star Biotech as a Series A round

Novo A/S invested $33M in AnaptysBio as a Series B round

January, 2007

Novo A/S invested $32.5M in Synosia Therapeutics as unattributed round

June, 2006

Novo A/S invested $16M in MediQuest Therapeutics as a Series A round

May, 2006

Novo A/S invested $4.1M in Celltrix as unattributed round

January, 2006

Novo A/S invested $25M in Symphogen as a Series D round

December, 2005

Novo A/S invested $67M in Light Sciences Oncology as a Series A round

November, 2005

Novo A/S invested $26.6M in PTC Therapeutics as unattributed round

1999

Novo A/S was founded in 1999